Podcasts about Early Stage

Not every SaaS success story starts with a multi-million-dollar seed round. While flashy headlines highlight startups raising big in Silicon Valley, most founders are left asking a far more practical question: Should I bootstrap, or go after funding? In this episode, we're joined by Denise Edwards, the founder of SaaS Launch, a platform that helps early-stage SaaS founders secure the right kind of capital and avoid the wrong kind of investor. We dive into the different types of funding available to SaaS founders and explain the real trade-offs between raising capital vs bootstrapping. Denise breaks down dilutive vs non-dilutive funding and what those terms actually mean for your business long-term. But it's not just about money. Denise highlights the intangible value investors can offer, like mentorship, industry connections, and strategic insights, that often outweigh the dollar signs. We also tackle some of the biggest myths and misconceptions founders believe about fundraising. Finally, Denise walks us through the anatomy of a great pitch, what to say, what to avoid, and how to stand out from the crowd. Whether you're scaling with your own savings or prepping for your first round, this episode will give you the tools and insight to make smarter funding decisions for your SaaS startup. Topics Discussed in this episode: How Denise went from working in SaaS to starting SaaS Launch(01:56) The different types of funding available to SaaS founders (06:30) The pros and cons of raising funding vs bootstrapping (09:00) Dilutive vs non-dilutive funding options (11:27) The intangible benefits that investors bring to the table (17:00) Common myths and misconceptions founders have about fundraising (20:00) The KPIs and metrics that investors look at (24:20) The biggest mistakes founders make when pitching investors (30:23) The anatomy of a great pitch (37:33) Mentions:  Empire Flippers Podcasts Empire Flippers Marketplace Create an Empire Flippers account Subscribe to our weekly newsletter SaaS Launch  Denise's LinkedIn Sit back, grab a coffee, and learn how to take the next step in your SaaS journey with confidence.  

Nnamdi Okike of 645 Ventures joins Nick to discuss From Power Law to Proprietary Insight: Unlocking Early-Stage Alpha, Data-Driven VC, and Building a Next-Gen Firm. In this episode we cover: Frameworks and Signals for Early-Stage Investing Challenges and Opportunities in Non-Consensus Investing The Role of AI in Venture Capital Guest Links: Nnamdi's LinkedIn Nnamdi's X 645 Ventures' LinkedIn 645 Ventures' Website The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area. Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.

In this episode, Kendra discusses something that most of us can relate to - the feeling of “falling behind” in business and why it's usually more perception than reality.She explains how comparing your journey to someone else's, especially those with more experience or different circumstances, can create unrealistic expectations and unnecessary pressure. Using the metaphor of business as a marathon, not a sprint, Kendra encourages listeners to stay focused on their own pace.Whether you're just starting out or feeling stuck in the learning curve, this episode offers perspective and reassurance that everyone's path to success looks different - and that's exactly how it should be.In this episode we cover:Addressing the Feeling of Being Behind (00:50)Comparison and Unrealistic Expectations (02:17)There is Double Work in Early Stages (03:43)The Sources of Feeling Behind (05:55)Reframing the Timeline (08:40)Better Define Your Progress (09:53) Leave the podcast a 5-star review: https://ratethispodcast.com/wealthy

Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions

Peter Schmid, FRCP, MD, PhD - Use of Neoadjuvant Chemoimmunotherapy Followed by Adjuvant Immunotherapy in Early-Stage TNBC: A Case-Based Discussion

Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions

The Matts again respond to your queries. They discuss whether we are witnessing the early stages of a global war without anyone admitting it, if we have collectively deleted our memory of 2016 and when we started confusing billionaires with philosophers. Plus there's talk of whether Keir Starmer should have stooped at the feet of Donald Trump, if having children is ethical and what actually defines genius.OFFER: Get The New World for just £1 for the first month. Head to https://www.thenewworld.co.uk/2matts Hosted on Acast. See acast.com/privacy for more information.

David Nothacker, Co-Founder und CEO von sennder, teilt seine wichtigsten Learnings aus dem Fundraising und dem Umgang mit Investoren. Er spricht über die Bedeutung von Board-Management, warum Time Limits und Shareholding-Limits für Board Seats entscheidend sind und wie man FOMO (Fear of Missing Out) bei Investoren erzeugt, um erfolgreiche Finanzierungsrunden zu gestalten. Was du lernst: Warum klare Regeln für Board Seats wichtig sind, um effiziente Entscheidungen zu treffen Wie du Fundraising-Prozesse strukturierst, um Wettbewerb und Interesse bei Investoren zu erzeugen Die Unterschiede zwischen Early-Stage- und Growth-Stage-Fundraising ALLES ZU UNICORN BAKERY: https://zez.am/unicornbakery  Mehr zu David: https://www.linkedin.com/in/david-nothacker/  sennder: https://www.sennder.com/de  Join our Founder Tactics Newsletter: 2x die Woche bekommst du die Taktiken der besten Gründer der Welt direkt ins Postfach: https://www.tactics.unicornbakery.de/ 

In this episode of the Digible Dudes Podcast, we sit down with Justin Jones, better known as The Multifamily AI Guy and AI Evangelist at Hyly.AI.From mindset shifts to machine learning, Justin brings a refreshing, human-first perspective to one of the most talked-about trends in property management: artificial intelligence. Whether you're a marketing exec, on-site leasing agent, or maintenance pro, this conversation will reshape how you think about AI's role in multifamily.This isn't about tech for tech's sake. It's about using AI to restore humanity to our workflows, empower teams, and help people find home.Like and subscribe for more!Digible:⁠ https://digible.com/Fiona: ⁠⁠⁠https://www.myfiona.com/Leave a Spotify Review: ⁠⁠⁠https://spoti.fi/3LfoEdU⁠⁠⁠Leave an Apple Review: ⁠⁠⁠https://apple.co/3AA2zRj⁠⁠(00:00) AI in Multifamily (04:45) Meet Justin Jones: The Multifamily AI Guy  (06:38) The Reality of AI Adoption  (09:46) Overcoming Job Fear in the Age of AI  (13:16) The Evolution of AI  (16:32) Building Marketing Campaigns with LLMs  (20:40) AI Literacy for Everyone  (26:44) MELDS Framework for AI Transformation  (31:19) Choosing the Right AI Stack  (35:47) Is AI in its Early Stage?(38:10) Why Fear Kills Innovation (and How to Fix It)  (40:09) Scale Linda: Retaining Tribal Knowledge with AI 

Richard Gearhart and Elizabeth Gearhart, co-hosts of Passage to Profit Show interview Judith Sheft from New Jersey Commission on Science, Innovation & Technology, Dr. Alberta “Tamika” Quick from Leading Young Women, Inc and Gaurav “G” Sharma from Hook.   How do you turn a brilliant idea into a funded startup? In this episode, innovation champion Judith Sheft, Executive Director of the New Jersey Commission on Science, Innovation and Technology (NJEDA), shares how early-stage entrepreneurs can access grants, connect with top researchers, and test their ideas through real customer feedback. From cutting-edge clean tech to video games that treat eye disorders, Judith spotlights how founders can tap into the ecosystem, find talent, and turn vision into venture—with support every step of the way. Read more at: https://www.njcsit.gov/   Gaurav “G” Sharma is the founder of Hook, the ultimate app for music remixing and mashups, giving you the freedom to express your creativity like never before. Remix your favorite songs and craft unique mashups in seconds. Whether you want to create viral sounds for reels or just have fun, Hook makes music remixing effortless and enjoyable. Browse their catalog of licensed tracks, let your creativity flow, and use AI-powered mashups, genre-based filters, and sound effects to shape your sound. Take it to the next level with video editing tools and seamless social media sharing—Hook is your creative playground. Read more at: https://hookmusic.com/   Dr. Alberta “Tamika” Quick is the founder of Leading Young Women, Inc., a community-engaged non-profit organization delivering enrichment programs that address leadership, identity, and empowerment for middle and high school girls through partnerships with New Jersey school districts. Leading Young Women, Inc. is led by successful women of color who look to effect positive change in the lives of young women living in underserved communities. As women leaders, they understand the importance of providing representation of, exposure to, and interactions with successful women from their communities. Read more at: https://www.leadingyoungwomen.com/   Whether you're a seasoned entrepreneur, a startup, an inventor, an innovator, a small business or just starting your entrepreneurial journey, tune into Passage to Profit Show for compelling discussions, real-life examples, and expert advice on entrepreneurship, intellectual property, trademarks and more. Visit https://passagetoprofitshow.com/ for the latest updates and episodes. Chapters (00:00:00) - Richard and Elizabeth on Starting a Business(00:00:24) - Passage to Profit(00:01:52) - What Advice Would You Give Yourself For Your Career?(00:04:55) - Who is the Commission on Science, Innovation and Technology in New Jersey(00:07:41) - What an Entrepreneur Should Do to Maximize Their Success(00:12:19) - What are some other angles to entrepreneurism that you can share with(00:15:22) - What Makes New Jersey a Good Place to Start a Business?(00:17:48) - Small Business Health Insurance Hotline(00:20:05) - Passage to Profit: How to Get Started(00:20:59) - Meet Judith Scheff, the New Jersey Commission on Science, Innovation(00:22:33) - China's 300,000 Patent Applications in AI vs US(00:28:00) - Elizabeth's Spotlight: Content Creation Studio(00:30:32) - Is AI Affecting Your Brain?(00:32:14) - Hook Music: A Social Media Platform for Music(00:37:27) - Hook Music Launches With Record Label Artists(00:39:43) - Startups: Getting Hook Music Launched(00:43:04) - Dr. Tamika Quick on Leading Young Women(00:48:32) - Supporting New Jersey Girls: Challenges(00:55:30) - Diamonds and GEMS: The program(00:58:04) - Leading Women: Going Mainstream(01:02:21) - Passage to Profit: Judah Sheft(01:03:25) - Secret to Success: Creativity, Identity(01:06:46) - Passive to Profit

Today, we’re bringing you the best from the KUOW newsroom… KUOW Immigration Reporter Gustavo Sagrero re-visits a high school senior near Bellingham, whose dad came to the U.S. without authorization about 20 years ago and was deported earlier this year. A day health center for disabled adults in Snohomish County is closing this summer – it’s the last facility of its kind in the entire county. And a theater program in Washington state is helping people with early-stage memory loss let loose with improv. We can only make Seattle Now because listeners support us. Tap here to make a gift and keep Seattle Now in your feed. Got questions about local news or story ideas to share? We want to hear from you! Email us at seattlenow@kuow.org, leave us a voicemail at (206) 616-6746 or leave us feedback online.See omnystudio.com/listener for privacy information.

Before President Trump and Elon Musk publicly cut ties last week, they were closely working together to identify government waste. The President even tapped Musk to lead the charge, appointing him as head of the newly formed Department of Government Efficiency. Months later,  Musk is now saying President Trump's "one big, beautiful bill," is undermining the work his team set out to do in the first place. Bret revisits his conversation with Elon Musk and the DOGE team from earlier this year, to take a look at what their initial goals and visions were, and how that compares with the work they've been able to do since.  Follow Bret on X: @BretBaier Learn more about your ad choices. Visit podcastchoices.com/adchoices

The world's most notorious criminals, unknowingly spilling their secrets on a 'secure' app run by... the cops. That's exactly what happened in Operation Ironside, a covert operation run by the FBI in collaboration with the AFP. Chris Craner is one of Australia’s most experienced tactical operators. His 30-plus-year career had him at the forefront of some of the country’s most intense and high-stakes investigations, including Ironside and the Lindt Cafe Siege. In this episode hosted by Brent Sanders, Chris shares exclusive details about the Lindt Cafe Siege, and pulls back the curtain on Ironside. Hear how authorities infiltrated the underbelly of organised crime syndicates, seizing millions in dirty cash, blocking large importations of drugs and intercepting homicide plots. If this content affected you, the number for Lifeline is 13 11 14. See omnystudio.com/listener for privacy information.

Today, we're visted by one of our favorite. Ilana Dunn Solomon—dating coach, content creator, and the voice behind Seeing Other People, a podcast that's basically the internet's wisest, funniest older sister. Ilana's known for cutting through the noise of modern dating with raw honesty, zero judgment, and the kind of insights that make you feel both called out and comforted.But today, she's not here alone. She brought backup—her husband, Jake Solomon. The man who went from first date to fiancé to full-on husband in a love story that has unfolded both publicly and privately, with all the chaos, clarity, and chemistry that comes with it.In this episode, we're diving into all of the hilarious, and deeply human moments that makes a marriage. We're talking about the difference between butterflies and real compatibility, and the myths people still believe about love.We're also talking dating app burnout, emotional availability, male perspectives, green flags, and everything that comes up when a dating expert marries someone who perhaps never expected to be part of the discourse...00:00 - Intro: Welcome Alana & Jake00:36 - How They Met: A Hinge Love Story02:02 - The Early Stages of Dating03:26 - First Impressions on Their First Date05:05 - COVID Dating & Timing06:22 - Was Dating a Dating Coach Intimidating?07:42 - Launching Seeing Other People08:24 - The Engagement Story10:49 - When She Knew He Was "The One"12:26 - Married Life & Moving In Together13:38 - Living Together Adjustments15:08 - The Great Sock Debate16:32 - Family Dynamics & Holidays18:57 - Marriage Myths That Aren't True20:09 - Dating Your Partner After Marriage21:04 - Their Best & Worst Dates24:43 - Newlywed Game: He Said / She Said31:24 - Dating Advice Men & Women Need to Hear32:59 - The Dating App Feature They Wish Existed34:39 - Are Nice Guys Out?36:16 - Why Aren't More Men at Singles Events?39:09 - The Fear of Rejection in Dating40:23 - Are We Obsessed With Being Chosen?43:30 - Advice for Burned-Out Daters45:26 - Managing Dating Expectations47:01 - Their Own First Dates Reflection48:09 - How Well Do You Know Each Other? Quiz50:27 - Closing & Final ThoughtsNew episodes every Monday. Subscribe for more real talk on dating, relationships, and everything in between.If you're loving the conversation, hit that like button, drop a comment with your thoughts, and hit subscribe for more unfiltered dating talk on First Round's on Me!Download FROM: https://firstroundsonme.coInstagram: / firstroundsonmeTikTok: / firstroundsonmeappJoe:https://www.instagram.com/firstroundsonjoe/Hannah :https://www.instagram.com/hannah_glasby/Exclusive Offer - Transform Your Dating Life Today!Say goodbye to swiping left and hello to real connections! First Round's On Me helps you skip the awkward stages and find meaningful matches. Get a FREE month of FROM's premium subscription—all you have to do is use our code DATING!

The sports world continues to shift with the NBA Finals here, baseball plays and golf on the horizon. This week we discuss how the NBA Playoffs have shaped up, MLB plays, and a preview of The RBC Canadian Open. Join co-host Jeff Hartman and Pez himself as they talk these picks, and more. This podcast is a part of the Fans First Sports Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today on Equity, Rebecca Bellan sits down with Crowdstrike co-founder and former CTO, Dmitri Alperovitch, to talk about the evolving cybersecurity landscape, the role of startups, and why he says we're living in a World on the Brink. Listen to the full episode to hear about: What early-stage secure-by-design startup founders are missing when it comes to maintaining security while building quickly and crisis management.  How AI export controls and global rivalries are reshaping innovation. What investors are really looking for when backing cybersecurity startups today. Equity will be back Friday with a behind-the-scenes look at TC Sessions: AI, so don't miss it! Equity is TechCrunch's flagship podcast, produced by Theresa Loconsolo, and posts every Wednesday and Friday.  Subscribe to us on Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod. For the full episode transcript, for those who prefer reading over listening, check out our full archive of episodes here. Credits: Equity is produced by Theresa Loconsolo with editing by Kell. We'd also like to thank TechCrunch's audience development team. Thank you so much for listening, and we'll talk to you next time. Learn more about your ad choices. Visit megaphone.fm/adchoices

From the archives: 5-28-22In the state of Idaho, a capital punishment case refers to a criminal case in which the defendant is accused of a crime that carries the possibility of receiving the death penalty as a punishment. Capital punishment, also known as the death penalty, is the legal imposition of death as a penalty for a serious crime.Here is a summary of what typically constitutes a capital punishment case in the state of Idaho:Eligible Crimes: Capital punishment in Idaho is primarily reserved for cases involving aggravated murder. Aggravated murder includes intentional killings with specific aggravating circumstances, such as murder for hire, multiple murders, or the murder of a child.Arrest and Indictment: The process begins with the arrest and indictment of the defendant for the alleged crime. The defendant is formally charged with the offense and is considered innocent until proven guilty.Prosecution and Defense: The case proceeds to trial where the prosecution presents evidence and argues for the defendant's guilt, while the defense presents its case to establish the defendant's innocence or to mitigate the severity of the crime.Sentencing Phase: If the defendant is found guilty of aggravated murder, a separate sentencing phase takes place. During this phase, both the prosecution and defense present additional evidence related to aggravating and mitigating factors to determine whether the death penalty is an appropriate punishment.Aggravating and Mitigating Factors: Aggravating factors are circumstances that make the crime more heinous or deserving of the death penalty, while mitigating factors are circumstances that may reduce the defendant's culpability. These factors may include the defendant's prior criminal record, the brutality of the crime, the defendant's mental state, or any evidence of remorse.Jury Decision: In Idaho, the jury plays a crucial role in determining the sentence. If the jury finds that one or more aggravating factors outweigh the mitigating factors, they can recommend the death penalty. However, if the jury unanimously finds that the mitigating factors outweigh the aggravating factors, they can recommend a sentence of life imprisonment without the possibility of parole.Judicial Review: Following the jury's recommendation, the trial judge must review the case and determine whether the death penalty is justified based on the evidence presented. The judge has the discretion to accept or reject the jury's recommendation.Execution: If the judge imposes the death penalty, the defendant may be executed by lethal injection, which is the sole method of execution in Idaho.In this episode, we take look at the chances for a capital punishment case against Bryan Kohberger and if the proseuction is prepared to go down that road.(commercial at 9:20)to contact me:bobbycapucci@protonmail.comsource:Bryan Kohberger Prosecutor Likely to Push for Death Penalty: Legal Expert (newsweek.com)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Segun Lawson, President and CEO of Thor Explorations (TSX.V: THX) (AIM: THX) (OTC: THXPF), joins us for a review of Q1 2025 operations and financials from its Segilola Gold mine, located in Nigeria, and for the Company's ongoing exploration and development programs in Nigeria, Senegal and Cote D'Ivoire.    Q1 2025 Financial Highlights   22,750 ounces ("oz") of gold sold (Q1 2024: 17,420 oz) with an average gold price of US$2,720 per oz (Q1 2024: US$2,033). Cash operating cost of US$711 per oz sold (Q1 2024: US$418) and all-in sustaining cost ("AISC") of US$950 per oz sold (Q1 2024: US$632). Revenue of US$64.0 million (Q1 2024: US$33.3 million). EBITDA of US$43.6 million (Q1 2024: US$23.2 million). A quarterly record Net Income of US$34.4 million (Q1 2024: US$12.4 million). Net Cash of US$24.7 million (Q1 2024: Net debt of US$14.3 million). Maiden quarterly dividend of C$0.0125 per share per quarter (C$0.05 per year)   This strong financial balance sheet with no debt is allowing the Company to increase exploration initiatives at all projects.   In Nigeria, there is ongoing near-mine exploration focused on testing depth extensions of the Segilola deposit, with a diamond drilling program targeting the continuity of high-grade shoots down-plunge to the south. Early results confirm mineralization below the current final pit design. Drilling returned encouraging high-grade intercepts both north and south of the existing resource, indicating the potential for extensions and new target areas beyond the current limits of the Segilola resource. Regional exploration efforts concentrated on geochemical sampling targeting structurally complex zones within the Ilesha Schist Belt identified through geological modelling as prospective for gold mineralization.   In Senegal, at the Douta Gold Project, workstreams in support of a Preliminary Feasibility Study ("PFS") were advanced during 2024 on the metallurgical test work, process flow sheets and resource update.  Exploration work focused on  at depth between the main Makosa resource base along the 6km strike from Makosa Tail to the northern extent of the deposit, with RC drilling targeting increased oxide resource definition at the parallel Makosa East Prospect. The discovery of the Baraka 3 Prospect in Douta West has had positive implications to the Douta PFS, but has delayed the delivery of this study as a result. This 3km of strike length of very wide near-surface oxide gold mineralization could be very import to the early economics in a development scenario of this Project, and thus the Baraka 3 drilling has been accelerated.   Wrapping up we discuss the exploration prospectivity over the 3 different exploration projects in Côte d'Ivoire: The Guitry Gold Project and two additional option agreements to acquire an 80% interest in the early-stage Boundiali Exploration permit and the Marahui Exploration permit. At these project the company is assessing target-generative geochemical surveys and sampling and mapping, with drilling planned for after rainy season in Q3 2025.     If you have any questions for Segun regarding Thor Explorations, then please email them into us at Fleck@kereport.com or at Shad@kereport.com.   *In full disclosure, Shad is a shareholder of Thor Explorations at the time of this interview.   Click here to follow the latest news from Thor Explorations

From the archives: 12-20-22On this edition of the morning update, we dive right back into the headlines from overnight and see where things currently stand as of this morning.(commercial at 7:07)to contact me:bobbycapucci@protonmail.comsource:Idaho college murders update: Moscow police say ‘progress' has been made | The IndependentBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls

This week's show is entitled, "Chewing Glass: Stories From an Early-Stage Entrepreneur" and my guest is Ben Henson, Co-Founder, CRO at Peel. Tune in to learn: How to transition from a successful career in marketing to entrepreneurship and find your path. The role of AI in creating efficient marketing solutions and addressing unmet market needs. Strategies for maintaining balance in life and work, especially during the chaotic phases of starting a business. Listen Now | Watch the video HERE   Matt interviews the best and brightest minds in sales and Marketing.  If you would like to be a guest on Sales Pipeline Radio send an email to acceleration@heinzmarketing.com. Sales Pipeline Radio was recently listed as one of 30 Best Sales Management Podcasts and Top 60 Sales Podcasts You can subscribe right at Sales Pipeline Radio and/or listen to full recordings of past shows everywhere you listen to podcasts! You can even ask Siri, Alexa and Google or search on Audible!  

In the evolving world of alternative investments, AICPA's "PE/VC" guide often is only a starting point in the valuation of complex financial instruments.  Valuation specialists in this field combine their experience with formal guidance and financial theory.  Ms. Antonella Puca, Managing Partner at BlueVal, wrote a book on “Early Stage Valuation, A Fair Value Perspective” that summarizes her studies and experience in this field.   We will discuss her journey and hear how she addresses: Presenting technical complexity in a clear and concise form Influence of the fair value perspective on the scope and perspective of the book Ongoing relevance of fair valuation concepts in an evolving industry and economy Continue reading to learn about key resources available at AICPA-CIMA.com to improve your valuation analyses. Guest: Antonella Puca, Partner, BlueVal Host: Howard Mah-Lee, Senior Manager, AICPA Valuation Services Please share your thoughts about the episode - click here to leave us a review   Want to get involved with future FVS conferences, committees, task forces, or the standing ovation program? Send a message to infoFVS@aicpa-cima.com RESOURCES FOR FURTHER EXPLORATION If you're using a podcast app that does not hyperlink to the resources, please visit our podcast platform to access the show notes with direct links.  Accounting and Valuation guides from AICPA  If you are an AICPA-FVS Section member see below for free access to these guides Valuation of Privately Held Companies Equity Securities Issued as Compensation Valuation of Portfolio Company Investments of Venture Capital and Private Equity Funds and Other Investment Companies Exclusive content available with AICPA FVS Section membership: Click here to join this active community of your FVS peers. You will get 16 credits of complimentary CPE and access to rich technical content Valuation of Privately Held Companies Equity Securities Issued as Compensation Valuation of Portfolio Company Investments of Venture Capital and Private Equity Funds and Other Investment Companies  The FVS Valuation Podcast archives  Valuing Complex Financial Instruments 409A Valuations - What You Need To Know Valuation Considerations in Equity Compensation Financial Instrument Valuation Series: SAFEs, Convertible Notes, and Embedded Derivatives LEARN MORE ABOUT THE FOLLOWING AICPA CREDENTIALS: Accredited in Business Valuation (ABV®) – Visit the home page and check out the ABV infographic Certified in the Valuation of Financial Instruments (CVFI®) – Visit the home page and check out the CVFI infographic Certified in Financial Forensics (CFF®) - Visit the home page and check out the CFF infographic This is a podcast from AICPA & CIMA, together as the Association of International Certified Professional Accountants. To enjoy more conversations from our global community of accounting and finance professionals, explore our network of free shows here. Your feedback and comments are welcomed at podcast@aicpa-cima.com  

There's a belief New Zealand's entering the early stages of an export-led recovery. Stats NZ data reveals it's at $1.4 billion in April, compared with a $12 million deficit last year. The dairy sector's been the big winner, up $601 million to $2.2 billion. Former Finance Minister Steven Joyce told Mike Hosking it's promising on the back of a tough three years in the sector. He says domestically people aren't spending a lot, so imports aren't coming in, but fortunately the world is buying more from us which is a great point in the cycle. LISTEN ABOVE See omnystudio.com/listener for privacy information.

From the archives: 5-28-22In the state of Idaho, a capital punishment case refers to a criminal case in which the defendant is accused of a crime that carries the possibility of receiving the death penalty as a punishment. Capital punishment, also known as the death penalty, is the legal imposition of death as a penalty for a serious crime.Here is a summary of what typically constitutes a capital punishment case in the state of Idaho:Eligible Crimes: Capital punishment in Idaho is primarily reserved for cases involving aggravated murder. Aggravated murder includes intentional killings with specific aggravating circumstances, such as murder for hire, multiple murders, or the murder of a child.Arrest and Indictment: The process begins with the arrest and indictment of the defendant for the alleged crime. The defendant is formally charged with the offense and is considered innocent until proven guilty.Prosecution and Defense: The case proceeds to trial where the prosecution presents evidence and argues for the defendant's guilt, while the defense presents its case to establish the defendant's innocence or to mitigate the severity of the crime.Sentencing Phase: If the defendant is found guilty of aggravated murder, a separate sentencing phase takes place. During this phase, both the prosecution and defense present additional evidence related to aggravating and mitigating factors to determine whether the death penalty is an appropriate punishment.Aggravating and Mitigating Factors: Aggravating factors are circumstances that make the crime more heinous or deserving of the death penalty, while mitigating factors are circumstances that may reduce the defendant's culpability. These factors may include the defendant's prior criminal record, the brutality of the crime, the defendant's mental state, or any evidence of remorse.Jury Decision: In Idaho, the jury plays a crucial role in determining the sentence. If the jury finds that one or more aggravating factors outweigh the mitigating factors, they can recommend the death penalty. However, if the jury unanimously finds that the mitigating factors outweigh the aggravating factors, they can recommend a sentence of life imprisonment without the possibility of parole.Judicial Review: Following the jury's recommendation, the trial judge must review the case and determine whether the death penalty is justified based on the evidence presented. The judge has the discretion to accept or reject the jury's recommendation.Execution: If the judge imposes the death penalty, the defendant may be executed by lethal injection, which is the sole method of execution in Idaho.In this episode, we take look at the chances for a capital punishment case against Bryan Kohberger and if the proseuction is prepared to go down that road.(commercial at 9:20)to contact me:bobbycapucci@protonmail.comsource:Bryan Kohberger Prosecutor Likely to Push for Death Penalty: Legal Expert (newsweek.com)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

About M2 THE ROCK - MICHAEL MOLTHAN:I'm Michael Molthan, host of The M2 The Rock Show—one of the fastest-growing podcasts and shows on self-improvement, mental health, addiction recovery, and spiritual transformation. I'm so grateful you're here.I started M2 The Rock in 2017 to bring you conversations designed to make you happier, healthier, and more healed. Through raw and unfiltered discussions with experts, celebrities, thought leaders, and athletes, we uncover new perspectives on personal growth, recovery, and overcoming life's toughest challenges.My Story:What sets my journey apart is that there wasn't just one rock bottom—there were many. From being a successful luxury homebuilder to falling into addiction, homelessness, crime, and eventually 27 mugshots and prison, my life was in absolute chaos.Addiction was my temporary escape from childhood trauma, but it only led to destruction.It wasn't until I hit the lowest point imaginable that I finally found true freedom, redemption, and purpose. After an unexpected early release from prison in 2017, I walked 300 miles back to Dallas to turn myself in—only to be miraculously pardoned and told to “pay it forward.”And that's exactly what I've been doing ever since.My MissionI believe that rock bottom is not the end—it's a stepping stone to something greater.My goal is to redefine what "rock bottom" means by helping others rebuild their Spirit, Mind, and Body. On M2 The Rock, I speak openly about trauma, addiction, recovery, and the power of transformation. I don't shy away from topics like:✅ Trauma & Addiction – Understanding the root causes✅ Self-Sabotage & Mental Health – Breaking negative cycles✅ Codependency & Enabling – How relationships impact recovery✅ 12-Step Programs & Spiritual Healing – Finding true freedom✅ Religious Trauma & Personal Growth – Healing from past wounds"Everyone Is An Addict."Whether it's substances, work, validation, or negative thinking, we all have something we struggle with.But recovery is possible, and transformation is real.

Early Stage Traction Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. In the very early stage of the life of a company, traction can be more than just revenue growth Here are some key traction points to look for. The founder has an idea. The founder has an idea and a pitch deck. The founder has an idea, a pitch deck, and an MVP or minimum viable product The founder has an idea, a pitch deck, an MVP, and a customer. The founder has an idea, a pitch deck, an MVP, and a customer with revenue. The founder has an idea, a pitch deck, an MVP, and a customer with revenue that is growing. The founder has an idea, a pitch deck, an MVP, a customer with revenue that is growing, and a repeatable process for signing up customers. By breaking the early stage into phases, one can better understand if the startup is making progress. Startup investors look for signs of traction and momentum in the deal before investing. Consider this more nuanced version of traction in assessing very early-stage startups.   Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.

From September 14, 2023. Hosted by Tony Darnell. Deep in the cosmos, NASA's Transiting Exoplanet Survey Satellite (TESS) has discovered four new worlds orbiting a pair of young stars. These planets are providing scientists with a glimpse into a little-understood stage of planetary evolution - the time when atmospheres are being formed.   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

Send us a textToday, I have Jason and Tina Marie Scott, certified life and relationship coaches, co-hosts of the Loving Beyond The I Do podcast, and authors of the bestselling book Manifest A Joy-Filled Relationship. With over 33 years of marriage and extensive experience in guiding couples and singles toward fulfilling, long-lasting relationships, they specialize in helping people develop emotional awareness, establish healthy communication, and create genuine, joyful connections. Today, they are here to speak on how to find authentic love and clarity in the dating world, and we'll break this down into three different subcategoriesDating with Intention: How to Attract the Right Relationship – Tips for singles to clarify what they're truly looking for and identify compatible partnersEmotional Awareness for Successful Dating – How understanding and managing emotions can improve dating experiences and lead to more fulfilling relationshipsBuilding Trust and Communication in the Early Stages of Dating – Essential strategies for establishing a strong foundation in new relationships.You can find Jason & Tina Marie Scott:https://www.instagram.com/legendaryrelationship/https://www.youtube.com/@legendaryrelationshiphttps://legendaryrelationship.com/Single? Download our dating app:https://subscribepage.io/ffO65LBuy our dating gameboard:https://p4kdatingapp.com/shop/Want some relationship advice? Leave a voice note:https://www.speakpipe.com/playing4keepsappSupport the show

This Week's Topics:Ryan Reynolds in Early Stages of Exploring a Deadpool/X-Men Team Up Movie ‘X-Men' Movie At Marvel Studios Circling ‘Thunderbolts*' DirectorKevin Feige Feelings on The "Homework Problem"Thunderbolts* Weekend 1 Box OfficeGo to http://OrganicPricedBooks.com and use the Promo Code - MARVELGUA to get $2 off on every order. Use our referral link listed below so they know you are a Marvel Alliance listener: https://organicpricedbooks.com/?ref=beat0bzbb68uSupport The Alliance On Patreon & Get Ad-Free, Exclusive, Early Episodes https://www.patreon.com/guanetwork Geek Ultimate Alliance Network Is Produced By GeekVerse Podcast www.geekverse.ca Network Schedule:Monday: Rangers Alliance (Bi-Weekly)Tuesday: A Walk Through the Multiverse (Bi-Weekly)Wednesday: The Animation NationThursday: Star Wars AllianceFriday: Marvel AllianceSaturday: DC AllianceSunday: World's Finest True Believers (Monthly)Follow the respective shows on Twitter so when they record live on GeekVerse Podcast Network you can join the chat and add to the conversation!

This Week's Topics:Ryan Reynolds in Early Stages of Exploring a Deadpool/X-Men Team Up Movie ‘X-Men' Movie At Marvel Studios Circling ‘Thunderbolts*' DirectorKevin Feige Feelings on The "Homework Problem"Thunderbolts* Weekend 1 Box OfficeGo to http://OrganicPricedBooks.com and use the Promo Code - MARVELGUA to get $2 off on every order. Use our referral link listed below so they know you are a Marvel Alliance listener: https://organicpricedbooks.com/?ref=beat0bzbb68uSupport The Alliance On Patreon & Get Ad-Free, Exclusive, Early Episodes https://www.patreon.com/guanetwork Geek Ultimate Alliance Network Is Produced By GeekVerse Podcast www.geekverse.ca Network Schedule:Monday: Rangers Alliance (Bi-Weekly)Tuesday: A Walk Through the Multiverse (Bi-Weekly)Wednesday: The Animation NationThursday: Star Wars AllianceFriday: Marvel AllianceSaturday: DC AllianceSunday: World's Finest True Believers (Monthly)Follow the respective shows on Twitter so when they record live on GeekVerse Podcast Network you can join the chat and add to the conversation!

Join host Nataraj as he speaks with Emily Gerber, founder and principal of SixEastern, a PR firm specializing in startups and tech companies. Emily shares her expertise on crafting effective PR strategies for early-stage startups and navigating the evolving media landscape.About the Episode:This episode demystifies the world of PR for tech founders. Emily differentiates PR from marketing, emphasizing the importance of earned media and credibility. She provides actionable advice on when to engage a PR firm, the types of media to target, and how to manage expectations. The conversation explores alternative strategies beyond traditional tech publications, including podcasts and new media platforms. Emily highlights the increasing importance of founders building their social profiles and telling authentic stories. She shares real-world examples of successful PR campaigns and offers valuable insights into navigating crisis communications.About the Guest and Host:Emily Gerber: Founder and Principal of SixEastern, a PR firm for startups and tech companies. Previously at Uber and Box. Connect with Emily: → Website: https://www.sixeastern.com/Nataraj: Host of the Startup Project podcast, Senior PM at Azure & Investor. → LinkedIn:   /natarajsindam  → Twitter: https://x.com/natarajsindam→ Email updates: ⁠https://startupproject.substack.com/⁠→ Website: ⁠⁠⁠https://thestartupproject.io⁠⁠⁠Timestamps:00:02 - Introduction and Guest Introduction00:45 - Emily's Background and PR for Tech Startups01:17 - PR vs. Marketing: Understanding the Difference03:13 - When to Engage a PR Firm: Seed vs. Series A05:40 - The Unique Landscape of AI Startup PR06:19 - Top Tier PR Firms and Their Specializations08:39 - Setting Expectations and Measuring PR Success09:18 - Pitching Podcasts vs. Traditional Media14:21 - The Problem with Automated PR Pitches16:42 - Storytelling for Series A to Series C Startups17:44 - Crafting the Founder's Message for Podcasts21:08 - The Trend of Founders Going Direct on Social Media24:15 - Why Elon Musk's Strategies Don't Work for Everyone25:26 - Concrete Examples of Successful PR Campaigns29:21 - Why Traditional Media Still Matters for Startups31:12 - Pitching to New Media Platforms32:00 - Organic vs. Strategic PR: Behind-the-Scenes Tactics34:12 - SEO for AI Search Engines and the Future of PR37:18 - PR Plus Marketing: Integrating Services38:47 - Emily's Current Media Consumption: TBPN42:39 - Mentors and Their Influence44:38 - Lessons Learned in PR45:40 - Crisis Communications at Uber48:16 - Ignored Sectors in Startup PR: Enterprise SoftwareSubscribe to Startup Project for more engaging conversations with leading entrepreneurs!→ Email updates: ⁠https://startupproject.substack.com/⁠#StartupProject #PR #PublicRelations #Startups #Tech #Media #Marketing #Communications #Founders #Entrepreneurship #TechCrunch #WallStreetJournal #Podcast #YouTube #AI #SixEastern

Is your DeFi startup struggling to take off because of lack of interest? If reputation (or the lack thereof) is hurting your chances of getting funding, you need MediaRise's content solution on hand. Find out more at https://mediarise.clientcabin.com/app/defi-distribution MediaRise City: Bronx Address: 5680 Broadway Website: https://mediarise.clientcabin.com/ Email: skeeteadvisorygroup@gmail.com

The Early Stages of a Park Development for Woodside's Filipino Community by Uptown Radio

In this episode, we sit down with Christine Larson, Head of Strategy & Operations at Modern Energy and interim COO at Industrial Sun, to explore how early-stage developers can thrive in a landscape defined by high complexity, capital intensity, and shifting market signals.Christine shares how Modern's model goes beyond funding—providing hands-on operational support like IT and accounting—so founders can focus on what really matters: building and scaling transformative energy projects.We dive into:Why Modern invests in niche, high-complexity infrastructure like green hydrogen and EV fleet chargingHow capital bottlenecks and tariff uncertainty are shaping developer riskWhy utility coordination and contract innovation are now mission-criticalHow partnerships, not just tech, will drive the future of energyChristine and James explore how strategic collaboration—between developers, capital partners, and load customers—is key to unlocking the next generation of clean energy infrastructure.Paces helps developers find and evaluate the sites most suitable for renewable development. Interested in a call with James, CEO @ Paces?

Revolutionizing Nonprofit Fundraising with AI: An Interview with PosterChild.ai CEO Leandrew Robinson In this episode, we delve into the innovative world of nonprofit fundraising with Leandrew Robinson, the CEO and founder of PosterChild.ai. Discover how their peer-to-peer fundraising strategy helped their first customer achieve a 350% increase in individual giving year over year. Leandrew shares his journey from e-commerce to social impact, the importance of authentic storytelling, and how AI can streamline nonprofit operations. Learn about the transformative power of AI in creating and curating content, and get insights into the future of nonprofit fundraising. Whether you're a nonprofit leader or curious about the intersection of AI and social good, this episode is packed with valuable takeaways. 00:00 Introduction to Poster Child's Success 00:45 Meet Lean Andrew Robinson 01:14 The Journey to Poster Child 01:37 The Concept of Crowdsource Storytelling 02:24 From E-commerce to Nonprofits 03:37 The Role of AI in Nonprofit Storytelling 03:49 Challenges in Nonprofit Storytelling 04:46 AI's Impact on Authentic Storytelling 07:30 Future of AI in Nonprofit Fundraising 10:58 Balancing Features and Focus in Startups 15:30 Adoption and Evolution of AI Tools 21:01 Early Adoption and Future Pitfalls 21:58 The Early Stages of AI Integration 24:23 Transitioning from E-commerce to Nonprofit 25:41 Challenges in the Nonprofit Sector 28:44 Effective Fundraising Strategies 34:47 The Importance of Serendipity and Networking 36:35 Rapid Fire Questions 40:36 Final Thoughts and Contact Information

In this episode of our CVC series, Andreas Munk Holm and our CVC in-house expert, Jeppe Høier, talk with Marika King, Head of PINC, the corporate venture arm of Paulig.Marika shares how PINC was born to accelerate core innovation and deliver long-term impact across health, sustainability, and food security. She explains why PINC goes earlier than most CVCs and how they leverage Paulig's R&D and cultural DNA to validate, support, and scale startups. Marika also offers candid reflections on governance structures, founder dynamics, and how her journey through burnout shaped her values as an investor.Here's what's covered:03:10 Early Stage Investments and Validation16:54 Governance and Structure of Pink Ventures24:00 Lessons in Structuring a Corporate Venture Fund26:34 Understanding the Role of a CVC27:03 Misconceptions About CVCs28:49 Flexibility and Patience in CVC Investments31:29 The Importance of Founder-Friendly A

The hosts dissect Attio's AI-native CRM disrupting traditional customer management and examine the surprisingly resilient seed/Series B funding landscape despite economic headwinds. Learn how AI is fundamentally changing go-to-market playbooks, enabling tech companies to scale faster than ever before, and which AI sales tools have genuine staying power.Thanks for tuning in! Join the free Topline Slack channel to connect with 600+ revenue leaders, share insights, and keep the conversation going beyond the podcast!Subscribe to the Topline Newsletter to get the latest industry developments and emerging go-to-market trends delivered to your inbox every Thursday.Tune into The Revenue Leadership Podcast with Kyle Norton every Wednesday. Kyle dives deep into the strategies and tactics that drive success for revenue leaders like Jason Lemkins of SaaStr, Stevie Case of Vanta, and Ron Gabrisko of Databricks.Key Moments:[02:07] AJ's Boating Adventure[04:05] Sam on Pavilion's CMO Summit and Personal Updates[06:56] Marketing and Revenue Insights[10:36] AI in Business[13:34] Economic Sentiment and Business Strategy[33:02] Hiring in Volatile Times[37:04] Compensation Strategies for Sales Teams[40:55] AI in Sales: A Conversation with an AI SDR Founder[48:06] The Future of AI in Sales and Marketing[01:00:15] Novel Uses of AI[01:08:54] Closing Remarks and Shoutouts

Gopi Rangan has invested in 29 early-stage startups from scratch. He shares a simple but powerful approach to picking the right VCs, structuring your pitch (long-term vision + short-term plan + fuzzy mid-term path), and proving you are the sort of founder every pre-seed investor craves. If you're raising a pre-seed or seed, Gopi's tips will make your process faster, more targeted, and a lot less painful.___Why You Should Listen1. The 2-minute test for "real" pre-seed investors – Spot VCs who truly lead early rounds vs. those who waste your time.2. His 3-step framework for finding your perfect lead – Forget the 100 investor pipeline. Zero in on 10 prospects who'll actually write a check.3. How to balance short-term execution with a massive mission – Win over pre-seed VCs by knowing your next 6 months and your 10-year ambition.4. Why "business acumen" beats everything – Gopi explains how it trumps domain expertise or brand-name credentials.5. When to be fuzzy, when to be precise – The counterintuitive approach that shows you're open to customer feedback while still having big vision.____KeywordsPre-seed Funding, Early-Stage VC, Business Acumen, Go-to-Market Strategy, Founder–Investor Fit, Strategic Networking, Seed Round Pitch, Warm Introductions, Mission-Driven Startups, Conviction Investing____(00:00:00) Why Ruthless Prioritization Wins(00:03:29) Why Investing at Pre-seed is Personal(00:08:36) Investing When There Are Still Typos in the Pitch Deck(00:12:23) Spotting Founders with Exceptional Business Acumen(00:17:21) Great Ideas in the Hands of the Right Founder(00:26:29) The Practical Guide to Raising Your Seed RoundSend me a message to let me know what you think!

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the updated recommendations and topics such as when SLNB can be omitted, when ALND is indicated, radiation and systemic treatment decisions after SLNB omission, and the role of SLNB in special circumstances. We discuss the importance of shared decision-making and other ongoing and future de-escalation trials that will expand knowledge in this space. Read the full guideline update, “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update” at www.asco.org/breast-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-00099       Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Ko Un "Clara" Park from Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dr. Mylin Torres from Glenn Family Breast Center at Winship Cancer Institute of Emory University, co-chairs on “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you, it's a pleasure to be here. Brittany Harvey: And before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Torres and Dr. Park, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To start us off, Dr. Torres, what is the scope and purpose of this guideline update on the use of sentinel lymph node biopsy in early-stage breast cancer? Dr. Mylin Torres: The update includes recommendations incorporating findings from trials released since our last published guideline in 2017. It includes data from nine randomized trials comparing sentinel lymph node biopsy alone versus sentinel lymph node biopsy with a completion axillary lymph node dissection. And notably, and probably the primary reason for motivating this update, are two trials comparing sentinel lymph node biopsy with no axillary surgery, all of which were published from 2016 to 2024. We believe these latter two trials are practice changing and are important for our community to know about so that it can be implemented and essentially represent a change in treatment paradigms. Brittany Harvey: It's great to hear about these practice changing trials and how that will impact these recommendation updates. So Dr. Park, I'd like to start by reviewing the key recommendations across all of these six overarching clinical questions that the guideline addressed. So first, are there patients where sentinel lymph node biopsy can be omitted? Dr. Ko Un "Clara" Park: Yes. The key change in the current management of early-stage breast cancer is the inclusion of omission of sentinel lymph node biopsy in patients with small, less than 2 cm breast cancer and a negative finding on preoperative axillary ultrasound. The patients who are eligible for omission of sentinel lymph node biopsy according to the SOUND and INSEMA trial are patients with invasive ductal carcinoma that is size smaller than 2 cm, Nottingham grades 1 and 2, hormone receptor-positive, HER2-negative in patients intending to receive adjuvant endocrine therapy, and no suspicious lymph nodes on axillary ultrasound or if they have only one suspicious lymph node, then the biopsy of that lymph node is benign and concordant according to the axillary ultrasound findings. The patients who are eligible for sentinel lymph node biopsy omission according to the SOUND and INSEMA trials were patients who are undergoing lumpectomy followed by whole breast radiation, especially in patients who are younger than 65 years of age. For patients who are 65 years or older, they also qualify for omission of sentinel lymph node biopsy in addition to consideration for radiation therapy omission according to the PRIME II and CALGB 9343 clinical trials. And so in those patients, a more shared decision-making approach with the radiation oncologist is encouraged. Brittany Harvey: Understood. I appreciate you outlining that criteria for when sentinel lymph node biopsy can be omitted and when shared decision making is appropriate as well. So then, Dr. Torres, in those patients where sentinel lymph node biopsy is omitted, how are radiation and systemic treatment decisions impacted? Dr. Mylin Torres: Thank you for that question. I think there will be a lot of consternation brought up as far as sentinel lymph node biopsy and the value it could provide in terms of knowing whether that lymph node is involved or not. But as stated, sentinel lymph node biopsy actually can be safely omitted in patients with low risk disease and therefore the reason we state this is that in both SOUND and INSEMA trial, 85% of patients who had a preoperative axillary ultrasound that did not show any signs of a suspicious lymph node also had no lymph nodes involved at the time of sentinel node biopsy. So 85% of the time the preoperative ultrasound is correct. So given the number of patients where preoperative ultrasound predicts for no sentinel node involvement, we have stated within the guideline that radiation and systemic treatment decisions should not be altered in the select patients with low risk disease where sentinel lymph node biopsy can be omitted. Those are the patients who are postmenopausal and age 50 or older who have negative findings on preoperative ultrasound with grade 1 or 2 disease, small tumors less than or equal to 2 cm, hormone receptor-positive, HER2-negative breast cancer who undergo breast conserving therapy. Now, it's important to note in both the INSEMA and SOUND trials, the vast majority of patients received whole breast radiation. In fact, within the INSEMA trial, partial breast irradiation was not allowed. The SOUND trial did allow partial breast irradiation, but in that study, 80% of patients still received whole breast treatment. Therefore, the preponderance of data does support whole breast irradiation when you go strictly by the way the SOUND and INSEMA trials were conducted. Notably, however, most of the patients in these studies had node-negative disease and had low risk features to their primary tumors and would have been eligible for partial breast irradiation by the ASTRO Guidelines for partial breast treatment. So, given the fact that 85% of patients will have node-negative disease after a preoperative ultrasound, essentially what we're saying is that partial breast irradiation may be offered in these patients where omission of sentinel node biopsy is felt to be safe, which is in these low risk patients. Additionally, regional nodal irradiation is something that is not indicated in the vast majority of patients where omission of sentinel lymph node biopsy is prescribed and recommended, and that is because very few of these patients will actually end up having pathologic N2 disease, which is four or more positive lymph nodes. If you look at the numbers from both the INSEMA and the SOUND trial, the number of patients with pathologic N2 disease who did have their axilla surgically staged, it was less than 1% in both trials. So, in these patients, regional nodal irradiation, there would be no clear indication for that more aggressive and more extensive radiation treatment. The same principles apply to systemic therapy. As the vast majority of these patients are going to have node-negative disease with a low risk primary tumor, we know that postmenopausal women, even if they're found to have one to three positive lymph nodes, a lot of the systemic cytotoxic chemotherapy decisions are driven by genomic assay score which is taken from the primary tumor. And therefore nodal information in patients who have N1 disease may not be gained in patients where omission of sentinel lymph node biopsy is indicated in these low risk patients. 14% of patients have 1 to 3 positive lymph nodes in the SOUND trial and that number is about 15% in the INSEMA trial. Really only the clinically actionable information to be gained is if a patient has four or more lymph nodes or N2 disease in this low risk patient population. So, essentially when that occurs it's less than 1% of the time in these patients with very favorable primary tumors. And therefore we thought it was acceptable to stand by a recommendation of not altering systemic therapy or radiation recommendations based on omission of sentinel nodes because the likelihood of having four more lymph nodes is so low. Dr. Ko Un "Clara" Park: I think one thing to add is the use of CDK4/6 inhibitors to that and when we look at the NATALEE criteria for ribociclib in particular, where node-negative patients were included, the bulk majority of the patients who were actually represented in the NATALEE study were stage III disease. And for stage I disease to upstage into anatomic stage III, that patient would need to have pathologic N2 disease. And as Dr. Torres stated, the rate of having pathologic N2 disease in both SOUND and INSEMA studies were less than 1%. And therefore it would be highly unlikely that these patients would be eligible just based on tumor size and characteristics for ribociclib. So we think that it is still safe to omit sentinel lymph node biopsy and they would not miss out, if you will, on the opportunity for CDK4/6 inhibitors. Brittany Harvey: Absolutely. I appreciate you describing those recommendations and then also the nuances of the evidence that's underpinning those recommendations, I think that's important for listeners. So Dr. Park, the next clinical question addresses patients with clinically node negative early stage breast cancer who have 1 or 2 sentinel lymph node metastases and who will receive breast conserving surgery with whole breast radiation therapy. For these patients, is axillary lymph node dissection needed? Dr. Ko Un "Clara" Park: No. And this is confirmed based on the ACOSOG Z0011 study that demonstrated in patients with 1 to 3 positive sentinel lymph node biopsy when the study compared completion axillary lymph node dissection to no completion axillary lymph node dissection, there was no difference. And actually, the 10-year overall survival as reported out in 2017 and at a median follow up of 9.3 years, the overall survival again for patients treated with sentinel lymph node biopsy alone versus those who were treated with axillary lymph node dissection was no different. It was 86.3% in sentinel lymph node biopsy versus 83.6% and the p-value was non-inferior at 0.02. And so we believe that it is safe for the select patients who are early stage with 1 to 2 positive lymph nodes on sentinel lymph node biopsy, undergoing whole breast radiation therapy to omit completion of axillary lymph node dissection. Brittany Harvey: Great, I appreciate you detailing what's recommended there as well. So then, to continue our discussion of axillary lymph node dissection, Dr. Torres, for patients with nodal metastases who will undergo mastectomy, is axillary lymph node dissection indicated? Dr. Mylin Torres: It's actually not and this is confirmed by two trials, the AMAROS study as well as the SENOMAC trial. And in both studies, they compared a full lymph node dissection versus sentinel lymph node biopsy alone in patients who are found to have 1 to 2 positive lymph nodes and confirmed that there was no difference in axillary recurrence rates, overall survival or disease-free survival. What was shown is that with more aggressive surgery completion axillary lymph node dissection, there were higher rates of morbidity including lymphedema, shoulder pain and paresthesias and arm numbness, decreased functioning of the arm and so there was only downside to doing a full lymph node dissection. Importantly, in both trials, if a full lymph node dissection was not done in the arm that where sentinel lymph node biopsy was done alone, all patients were prescribed post mastectomy radiation and regional nodal treatment and therefore both studies currently support the use of post mastectomy radiation and regional nodal treatment when a full lymph node dissection is not performed in these patients who are found to have N1 disease after a sentinel node biopsy. Brittany Harvey: Thank you. And then Dr. Park, for patients with early-stage breast cancer who do not have nodal metastases, can completion axillary lymph node dissection be omitted? Dr. Ko Un "Clara" Park: Yes, and this is an unchanged recommendation from the earlier ASCO Guidelines from 2017 as well as the 2021 joint guideline with Ontario Health, wherein patients with clinically node-negative early stage breast cancer, the staging of the axilla can be performed through sentinel lymph nodal biopsy and not completion axillary lymph node dissection. Brittany Harvey: Understood. So then, to wrap us up on the clinical questions here, Dr. Park, what is recommended regarding sentinel lymph node biopsy in special circumstances in populations? Dr. Ko Un "Clara" Park: One key highlight of the special populations is the use of sentinel lymph node biopsy for evaluation of the axilla in clinically node negative multicentric tumors. While there are no randomized clinical trials evaluating specifically the role of sentinel lymph nodal biopsy in multicentric tumors, in the guideline, we highlight this as one of the safe options for staging of the axilla and also for pregnant patients, these special circumstances, it is safe to perform sentinel lymph node biopsy in pregnant patients with the use of technetium - blue dye should be avoided in this population. In particular, I want to highlight where sentinel lymph node biopsy should not be used for staging of the axilla and that is in the population with inflammatory breast cancer. There are currently no studies demonstrating that sentinel lymph node biopsy is oncologically safe or accurate in patients with inflammatory breast cancer. And so, unfortunately, in this population, even after neoadjuvant systemic therapy, if they have a great response, the current guideline recommends mastectomy with axillary lymph node dissection. Brittany Harvey: Absolutely. I appreciate your viewing both where sentinel lymph node can be offered in these special circumstances in populations and where it really should not be used. So then, Dr. Torres, you talked at the beginning about how there's been these new practice changing trials that really impacted these recommendations. So in your view, what is the importance of this guideline update and how does it impact both clinicians and patients? Dr. Mylin Torres: Thank you for that question. This update and these trials that inform the update represent a significant shift in the treatment paradigm and standard of care for breast cancer patients with early-stage breast cancer. When you think about it, it seems almost counterintuitive that physicians and patients would not want to know if a lymph node is involved with cancer or not through sentinel lymph node biopsy procedure. But what these studies show is that preoperative axillary ultrasound, 85% of the time when it's negative, will correctly predict whether a sentinel lymph node is involved with cancer or not and will also be negative. So if you have imaging that's negative, your surgery is likely going to be negative. Some people might ask, what's the harm in doing a sentinel lymph node biopsy? It's important to recognize that upwards of 10% of patients, even after sentinel lymph node biopsy will develop lymphedema, chronic arm pain, shoulder immobility and arm immobility. And these can have a profound impact on quality of life. And if there is not a significant benefit to assessing lymph nodes, particularly in someone who has a preoperative axillary ultrasound that's negative, then why put a patient at risk for these morbidities that can impact them lifelong? Ideally, the adoption of omission of sentinel lymph node biopsy will lead to more multidisciplinary discussion and collaboration in the preoperative setting especially with our diagnostic physicians, radiology to assure that these patients are getting an axillary ultrasound and determine how omission of sentinel lymph node biopsy may impact the downstream treatments after surgery, particularly radiation and systemic therapy decisions, and will be adopted in real world patients, and how clinically we can develop a workflow where together we can make the best decisions for our patients in collaboration with them through shared decision making. Brittany Harvey: Absolutely. It's great to have these evidence-based updates for clinicians and patients to review and refer back to. So then finally, Dr. Park, looking to the future, what are the outstanding questions and ongoing trials regarding sentinel lymph node biopsy in early-stage breast cancer? Dr. Ko Un "Clara" Park: I think to toggle on Dr. Torres's comment about shared decision making, the emphasis on that I think will become even more evident in the future as we incorporate different types of de-escalation clinical studies. In particular, because as you saw in the SOUND and INSEMA studies, when we de-escalate one modality of the multimodality therapy, i.e., surgery, the other modalities such as radiation therapy and systemic therapy were “controlled” where we were not de-escalating multiple different modalities. However, as the audience may be familiar with, there are other types of de-escalation studies in particular radiation therapy, partial breast irradiation or omission of radiation therapy, and in those studies, the surgery is now controlled where oftentimes the patients are undergoing surgical axillary staging. And conversely when we're looking at endocrine therapy versus radiation therapy clinical trials, in those studies also the majority of the patients are undergoing surgical axillary staging. And so now as those studies demonstrate the oncologic safety of omission of a particular therapy, we will be in a position of more balancing of the data of trying to select which patients are the safe patients for omission of certain types of modality, and how do we balance whether it's surgery, radiation therapy, systemic therapy, endocrine therapy. And that's where as Dr. Torres stated, the shared decision making will become critically important. I'm a surgeon and so as a surgeon, I get to see the patients oftentimes first, especially when they have early-stage breast cancer. And so I could I guess be “selfish” and just do whatever I think is correct. But whatever the surgeon does, the decision does have consequences in the downstream decision making. And so the field really needs to, as Dr. Torres stated earlier, rethink the workflow of how early-stage breast cancer patients are brought forth and managed as a multidisciplinary team. I also think in future studies the expansion of the data to larger tumors, T3, in particular,reater than 5 cm and also how do we incorporate omission in that population will become more evident as we learn more about the oncologic safety of omitting sentinel lymph node biopsy. Dr. Mylin Torres: In addition, there are other outstanding ongoing clinical trials that are accruing patients right now. They include the BOOG 2013-08 study, SOAPET, NAUTILUS and the VENUS trials, all looking at patients with clinical T1, T2N0 disease and whether omission of sentinel lymph node biopsy is safe with various endpoints including regional recurrence, invasive disease-free survival and distant disease-free survival. I expect in addition to these studies there will be more studies ongoing even looking at the omission of sentinel lymph node biopsy in the post-neoadjuvant chemotherapy setting. And as our imaging improves in the future, there will be more studies improving other imaging modalities, probably in addition to axillary ultrasound in an attempt to accurately characterize whether lymph nodes within axilla contain cancer or not, and in that context whether omission of sentinel lymph node biopsy even in patients with larger tumors post-neoadjuvant chemotherapy may be done safely and could eventually become another shift in our treatment paradigm. Brittany Harvey: Yes. The shared decision making is key as we think about these updates to improve quality of life and we'll await data from these ongoing trials to inform future updates to this guideline. So I want to thank you both so much for your extensive work to update this guideline and thank you for your time today. Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you. Dr. Ko Un "Clara" Park: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

I'm pulling back the curtain on the three biggest mistakes that cause early-stage food entrepreneurs to struggle and often fail. Drawing from my experience over 7+ years helping hundreds of food businesses launch and scale, I give you an honest look at why so many passionate food makers hit roadblocks despite having amazingly delicious products.You'll discover why listening to everyone's conflicting opinions leads to confusion rather than clarity, how spreading yourself too thin across multiple sales channels sabotages your momentum, and the surprising cost of operating without a proper long-term plan or budget. More importantly, I share practical solutions for each of these pitfalls, including how to filter advice, strategically choose your sales channels, and create a vision-driven plan that actually works.Whether you're still in the dreaming phase or already knee-deep in your food business journey, this episode delivers the tough love and actionable strategies you need to avoid common traps and set your business up for sustainable success. Don't miss this essential guide to navigating the early stages of your food business with confidence!Stop the endless research and overwhelm! Know exactly what each sales channel looks like for success and create a roadmap for your unique business - join me in the Sales Channel Challenge - 3 days April 15, 16 and 17. Reserve your space for just $27 at https://www.foodbizsuccess.com/challenge MAKE A BIG LEAP THIS YEAR! Commit to the support and accountability you need to create a beautiful business! Get Food Business Success to launch and scale to $100K guaranteed Scale your existing business to $300K in 2025 with the financial and operational foundations and become the CEO of your biz in Master Your Business Pick up your copy of "Key Ingredients" on Amazon here. Check out my YouTube channel at www.foodbiz.tube for how to videos to start and grow a packaged food business.

Synopsis: Building in biotech isn't for the faint of heart—especially during a market downturn. But that's exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech's toughest cycles—and emerged stronger each time. Hosted by Rahul Chaturvedi, this conversation dives into what it really takes to launch and scale biotech companies: from mastering the evolution of the CEO role to raising nearly $900M through strategic partnerships, to knowing when it's time to pass the torch. Steve also shares how Mission BioCapital is rewriting the playbook for early-stage innovation through its Platinum Program, offering $500K and lab access to science founders ready to launch bold new ideas. Real talk, real strategies, and a blueprint for building lasting biotech companies—especially when its hardest. Biography: Steve Tregay, PhD is a Managing General Partner based in our Cambridge office. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and Nocion Therapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares. Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma. Steve received his doctoral and Master's degrees in organic chemistry from Harvard University and a Bachelor's from Davidson College.

It's not uncommon for brands to scale mostly as B2B enterprises with minimal emphasis on sophisticated consumer marketing. When product design carries you that far, it can be easy to overlook the marketing department. Then, when you turn to ask them for acceleration, you realize you do not have the right team at all. Or, even worse, you don't even believe. For the founders who delay and doubt the power of marketing, please have a listen. Your Host: Dr. James F. Richardson of Premium Growth Solutions, LLC www.premiumgrowthsolutions.com Please send feedback on this or other episodes to: admin@premiumgrowthsolutions.com

This week, our host, Erica Wenger, shares a number of practical and unconventional tips on how to fundraise effectively as an early-stage founder!In this episode, Erica breaks down the fundraising process beyond the typical advice, offering insights on how to approach investors, craft a compelling narrative, and stand out in a crowded market. She challenges common misconceptions about fundraising and highlights creative strategies founders can use to secure capital—whether through unconventional networking, alternative funding sources, or leveraging unique market positioning.If you're an early-stage founder navigating the fundraising landscape, this episode is packed with actionable insights to help you raise capital with confidence!Follow Us!Erica Wenger: @erica_wengerDear Twentysomething: @deartwentysomethingRead less

When you've built a wildly successful business and suddenly feel the urge to pivot, what do youdo? In this candid solo episode, host Danielle McCleerey shares her personal experiencenavigating a massive business shift—while already running a thriving six and seven-figureenterprise. If you've ever felt the pull to evolve but feared the unknown, this episode is yourpermission slip to trust your intuition, embrace transformation, and move forward with clarity.Danielle also unpacks the emotional, financial, and strategic realities of pivoting at a high level,why nervous system regulation is key, and what most people don't realize about making bigcareer shifts.

Senior NBA Writer for The Athletic, Sam Amick, joins Papa & Silver to reflect on Steph Curry's unprecedented journey to 4,000 three-pointers and how he overcame the ankle injuries that derailed the early stages of his career See omnystudio.com/listener for privacy information.

In this episode, I dive deep into the intricacies of tax season and how it's affecting business owners. We'll explore common questions around tax deductions, tax savings, and the strategies that are often suggested by various sources on the internet. While there are many legitimate strategies out there, I highlight the potential pitfalls and time costs related to overcomplicating your tax approach.   Through real-life anecdotes and practical advice, I urge you to reallocate your time towards activities that drive business growth, rather than spending countless hours on tax strategies that yield minimal returns. This episode encourages business owners to focus on building a profitable, high-value enterprise and to use simpler, effective tax practices that don't distract from the primary mission of growing their business. Tune in to understand how to balance tax savings with business productivity and set yourself up for long-term success.   What You'll hear in this episode: [0:50] Common Tax Questions During Tax Season [1:15] Overthinking Tax Deductions [2:00] Evaluating Tax Strategies [3:25] The Cost of Maintaining Tax Strategies [4:25] Focusing on Business Growth Over Tax Savings [5:55] When Tax Strategies Make Sense [7:55] The Importance of Developing Good Habits in The Early Stage of a Business   If you like this episode, check out: What Entrepreneurs Need to Know About Tax Deductions The Truth About Tax Savings and Strategies Is Hiring A Tax Strategist For You?   Want to learn more so you can earn more?  Visit keepwhatyouearn.com to dive deeper on our episodes  Visit keepwhatyouearncfo.com to work with Shannon and her team  Watch this episode and more here: https://www.youtube.com/channel/UCMlIuZsrllp1Uc_MlhriLvQ  Connect with Shannon on IG: https://www.instagram.com/shannonkweinstein/   The information contained in this podcast is intended for educational purposes only and is not individual tax advice. Please consult a qualified professional before implementing anything you learn.

Natalie explores why we feel so disappointed in early dating - is it the other person letting us down, or are we falling for our own fantasies? Learn to recognize when you're dating your imagination instead of the real person sitting across from you. Episode show notes: https://www.baggagereclaim.co.uk/289 Save 30% on Relationship Fundamentals classes: Readying for Love | Overcoming Dating Anxiety | The Compatibility Factor | Could This Be It? | Know Where You Stand | Co-Piloting Your Relationship Leave a voice note: https://www.speakpipe.com/baggagereclaim  Support the podcast and leave a tip: https://baggagereclaim.ck.page/products/podcast  'Reclaimed' membership: https://www.baggagereclaim.co.uk/reclaimed/ Work with me: https://www.baggagereclaim.co.uk/consultations/ Baggage Reclaim: https://www.baggagereclaim.co.uk  Shop courses and books: https://store.baggagereclaim.com Sign up for my newsletter: https://www.baggagereclaim.co.uk/newsletter/      

This episode discusses financial independence strategies, including Barista FI and Coast FI, along with insights into inherited accounts post-Secure Act (2020). Listeners will learn about health insurance considerations in early retirement, the dynamics of inherited IRAs, and how to manage finances during entrepreneurial transitions. The discussion highlights the importance of treating business expenses as valid investments and navigating inheritance with strategic planning. Timestamps & Key Takeaways: 00:01:28 Introduction to Barista FI and Coast FI Key Insight: Barista FI allows early withdrawals from retirement savings while supplementing income through part-time work. Takeaway: Understand the mechanics of Barista FI to reduce stress from job pressure when planning retirement. 00:04:13 Health Insurance Challenges in Early Retirement Key Insight: Health insurance costs can significantly impact your early retirement plans. Actionable Takeaway: Assess your health insurance situation and potential subsidies if considering early retirement. 00:19:08 Understanding Inherited Accounts Post-Secure Act Key Insight: The Secure Act requires non-spouse beneficiaries to deplete inherited retirement accounts within 10 years. Actionable Takeaway: Ensure all retirement accounts have updated beneficiary designations to avoid complications. 00:23:39 Simplifying Inherited IRA Management Key Insight: Spouses can assume the inherited IRA as their own, providing greater flexibility and simpler management. Takeaway: Review spouse beneficiary options when dealing with inherited accounts for optimal tax outcomes. 00:26:11 Using a Brokerage Account for Inheritance Advantages Key Insight: Brokerage accounts benefit from a step-up in basis, allowing heirs to sell securities with no capital gains tax immediately. Actionable Takeaway: Explore how to effectively utilize brokerage accounts for tax efficiency in inheritance. 00:45:58 Freedom from Inherited Advisors Key Insight: Remember, you are not obligated to keep the inherited advisor when managing inherited accounts. Takeaway: Take time to assess whether to maintain or change financial advisory relationships after inheriting accounts. 00:50:09 Investment Approaches in Early Stages of Entrepreneurship Key Insight: Treat your startup costs as investments in yourself and factor in the inherent risks. Action Item: Give yourself permission to direct resources into your business, rather than traditional savings during early entrepreneurship. Actionable Takeaways: Health Insurance Planning: Run the numbers for potential health insurance options based on your anticipated income when planning for early retirement. Beneficiary Check: Verify that all retirement accounts have up-to-date beneficiary designations to prevent issues for heirs. Business as an Investment: Reflect on viewing your business endeavors as valid investments, allowing you to adapt your financial strategy accordingly during entrepreneurial journeys. Quotes to Note: "Health insurance costs can significantly impact your early retirement plans." - Rachael Camp 00:04:13 "Spouses should ideally assume the inherited IRA as their own for simplicity." - Rachael Camp 00:23:39 "You don't have to inherit an advisor when you inherit accounts." - Rachael Camp 00:45:58 Related Resources: The Secure Act Detailed Explanation Health Insurance Subsidy Calculator Discussion Questions: How can understanding Barista FI change your approach to work and retirement? What strategies can help when dealing with inherited accounts? How does the Secure Act impact your financial planning for generational wealth?